GSK’s bid for Human Genome Sciences rejected
pharmafile | April 19, 2012 | News story | Sales and Marketing | Benlysta, GSK, Human Genome Sciences, mergers and acquisitions
GlaxoSmithKline has launched a takeover bid for Human Genome Sciences for around $2.5 billion, but has been rejected by the US-based firm.
GSK and HGS launched their co-developed lupus treatment Benlysta last year, but has produced disappointing sales in its first year.
GSK has struck now because its partner’s share price has dropped by 76% since last year, largely due to Benlysta’s underwhelming performance.
The two companies are also collaborating on two further drugs – darapladib for the hardening of the arteries, and albiglutide for diabetes and heart failure.
HGS also has in its pipeline ABthrax (raxibacumab) for treating inhalation anthrax. The company has an agreed order for ABthrax with US Strategic National Stockpile, but must first gain FDA approval for the product.
The HGS Board says the offer does not reflect the company’s value, and is now exploring ‘strategic alternatives’ which include a potential sale of the firm.
The company says GSK is not excluded from this process – i.e., it is open to an improved offer. Meanwhile HGS has requested additional information on the progress of darapladib and albiglutide, the development of which is now being managed by GSK. HGS holds a stake in the molecules, and needs to assess how valuable they are before approaching any other potential buyers.
Andrew McConaghie
Related Content
GSK’s Jemperli accepted for FDA review for endometrial cancer treatment
GSK has announced that the US Food and Drug Administration (FDA) has accepted its supplemental …
GSK shares results from phase 3 trial for gonorrhoea treatment
GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential …
GSK’s meningococcal vaccine candidate accepted for FDA review
GSK has announced that the US Food and Drug Administration (FDA) has accepted for review …